XTalks
AUGUST 2, 2023
Clinical trials have shown that the vaccine is 90 percent effective in preventing shingles for individuals aged 50 and over. 2) Xevudy (sotrovimab) Xevudy, a monoclonal antibody treatment for SARS-CoV-2, generated £2.31 It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy.
The Pharma Data
DECEMBER 23, 2020
24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .
The Pharma Data
DECEMBER 23, 2020
COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S. This agreement is in addition to the recently announced advanced purchase commitments of more than 140 million doses of COVAXX’s UB-612 vaccine, totaling over $2.8
Expert insights. Personalized for you.
98 
Let's personalize your content